Single/Multiple Dose Escalation Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BAY1101042 Given as 5 mg MR Tablet After Single Oral Dosing Followed by Once Daily Dosing for 7 Days in 12 Healthy Male Subjects Per Dose Step in a Randomized, Placebo Controlled, Single Blind, Group Comparison Design

Trial Profile

Single/Multiple Dose Escalation Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BAY1101042 Given as 5 mg MR Tablet After Single Oral Dosing Followed by Once Daily Dosing for 7 Days in 12 Healthy Male Subjects Per Dose Step in a Randomized, Placebo Controlled, Single Blind, Group Comparison Design

Recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Jul 2018

At a glance

  • Drugs BAY 1101042 (Primary)
  • Indications Unspecified
  • Focus Adverse reactions
  • Sponsors Bayer
  • Most Recent Events

    • 16 Jul 2018 Planned number of patients changed from 72 to 108.
    • 16 Jul 2018 Planned End Date changed from 6 Jun 2018 to 26 Apr 2019.
    • 16 Jul 2018 Planned primary completion date changed from 8 May 2018 to 21 Mar 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top